Literature DB >> 16307011

Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.

F Cervantes1, A Alvarez-Larrán, E Arellano-Rodrigo, M Granell, A Domingo, E Montserrat.   

Abstract

Thrombosis is a frequent complication of polycythemia vera and essential thrombocythemia, but its incidence and predisposing factors in idiopathic myelofibrosis (IM) are unknown. In 18 (11.6%) of 155 patients diagnosed with IM in a single institution, 31 thrombotic events (19 arterial, 12 venous) were registered after a mean follow-up of 4.2 (s.d.: 4.5) years. In six patients, the thrombosis was simultaneous to or appeared a few months before IM diagnosis and 14 had one or more thrombotic episodes. When compared with the general population, a significant increase was observed in the incidence of venous thrombosis (odds ratio 17.5, 95% confidence interval: 10.3-31.4). At multivariate analysis, the initial variables associated with an increased risk of thrombosis were thrombocytosis (platelets >450 x 10(9)/l, P=0.001), presence of one cardiovascular risk factor (arterial hypertension, smoking, hypercholesterolemia, or diabetes, P=0.003), cellular phase of myelofibrosis (P=0.005), and Hb >11 g/dl (P=0.02). Considering post-diagnosis events, the 5-year thrombosis-free survival probability was 90.4% in the series, 80.6% for patients with platelets >450 x 10(9)/l, 82.6% for patients with one cardiovascular risk factor, and 85.1% for those in cellular phase. These results indicate an increased thrombotic risk for IM patients with hyperproliferative features and/or coexistent cardiovascular risk factors.

Entities:  

Mesh:

Year:  2006        PMID: 16307011     DOI: 10.1038/sj.leu.2404048

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  Pulmonary extramedullary haematopoiesis.

Authors:  Veenu Mubarak; Stephen Fanning; Morgon Windsor; Edwina Duhig; Simon Bowler
Journal:  BMJ Case Rep       Date:  2011-12-02

2.  Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis.

Authors:  Eva Zetterberg; Maria Verrucci; Fabrizio Martelli; Maria Zingariello; Laura Sancillo; Emanuela D'Amore; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Platelets       Date:  2013-10-31       Impact factor: 3.862

Review 3.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

Review 4.  JAK2 mutation and thrombosis in the myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

5.  The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.

Authors:  Annet Kirabo; Sung O Park; Anurima Majumder; Meghanath Gali; Mary K Reinhard; Heather L Wamsley; Zhizhuang Joe Zhao; Christopher R Cogle; Kirpal S Bisht; György M Keserü; Peter P Sayeski
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

6.  Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

Authors:  Michelle Ann Elliott; Animesh Pardanani; Terra L Lasho; Susan M Schwager; Ayalew Tefferi
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

Review 7.  Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.

Authors:  Orly Leiva; Gabriela Hobbs; Katya Ravid; Peter Libby
Journal:  JACC CardioOncol       Date:  2022-06-21

8.  Portal hypertension and myeloproliferative neoplasms: a relationship revealed.

Authors:  Ahmet Burak Toros; Serkan Gokcay; Guven Cetin; Muhlis Cem Ar; Yesim Karagoz; Besir Kesici
Journal:  ISRN Hematol       Date:  2013-09-16

Review 9.  Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review.

Authors:  Roxana Elena Bohîlţea; Monica Mihaela Cîrstoiu; Crîngu Antoniu Ionescu; Emilia Niculescu-Mizil; Ana Maria Vlădăreanu; Irina Voican; Mihai Dimitriu; Natalia Turcan
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

10.  Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.

Authors:  Nur Soyer; İbrahim C Haznedaroğlu; Melda Cömert; Demet Çekdemir; Mehmet Yılmaz; Ali Ünal; Gülsüm Çağlıyan; Oktay Bilgir; Osman İlhan; Füsun Özdemirkıran; Emin Kaya; Fahri Şahin; Filiz Vural; Güray Saydam
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.